GILEAD SCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
GILEAD SCIENCES, INC. (GILD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 0.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-02-24
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2025 was 0.70%, a 99.40% decline from fiscal 2024.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 117.40%, a 8930.77% increase from fiscal 2023.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 1.30%, a 7.14% decline from fiscal 2022.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 1.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.70% 10-K · filed 2026-02-24 | |
| 2024-12-31 | 117.40% 10-K · filed 2026-02-24 | 117.30% 10-K · filed 2025-02-28 |
| 2023-12-31 | 1.30% 10-K · filed 2026-02-24 | |
| 2022-12-31 | 1.40% 10-K · filed 2025-02-28 | |
| 2021-12-31 | 0.00% 10-K · filed 2024-02-23 | |
| 2020-12-31 | 56.20% 10-K · filed 2023-02-22 | |
| 2019-12-31 | 0.00% 10-K · filed 2022-02-23 | |
| 2018-12-31 | 0.00% 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |